{"abstract":"The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled \"Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment.\" The draft guidance was prepared by the Division of Gastroenterology in the Center for Drug Evaluation and Research at FDA to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease. The draft guidance provides FDA's recommendations about the necessary attributes of clinical studies for drugs being developed for the treatment of pediatric ulcerative colitis or pediatric Crohn's disease, including study population, study design, efficacy considerations, and safety assessments.","action":"Notice of availability.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/07/19/2024-15942.html","cfr_references":[],"citation":"89 FR 58743","comment_url":null,"comments_close_on":"2024-09-17","correction_of":null,"corrections":[],"dates":"Submit either electronic or written comments on the draft guidance by September 17, 2024 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.","disposition_notes":null,"docket_ids":["Docket No. FDA-2024-D-2682"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":1,"comment_start_date":"2024-07-19","updated_at":"2024-09-03T17:13:29.627-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2024-D-2682-0001","allow_late_comments":false,"id":"FDA-2024-D-2682-0001","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2024-D-2682","title":"Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability"}],"document_number":"2024-15942","effective_on":null,"end_page":58744,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/07/19/2024-15942.xml","html_url":"https://www.federalregister.gov/documents/2024/07/19/2024-15942/pediatric-inflammatory-bowel-disease-developing-drugs-for-treatment-draft-guidance-for-industry","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-15942?publication_date=2024-07-19","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-07-19/2024-15942/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":298,"last_updated":"2026-04-04 14:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-07-19/pdf/2024-15942.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-15942.pdf?1721306729","publication_date":"2024-07-19","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/07/19/2024-15942.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":1,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2024-D-2682","supporting_documents_count":0,"docket_id":"FDA-2024-D-2682","document_id":"FDA-2024-D-2682-0001","regulation_id_number":null,"title":"Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability","checked_regulationsdotgov_at":"2024-07-23T13:00:10Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":58743,"subtype":null,"title":"Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment; Draft Guidance for Industry; Availability","toc_doc":"Pediatric Inflammatory Bowel Disease:  Developing Drugs for Treatment","toc_subject":"Guidance:\n","topics":[],"type":"Notice","volume":89}